Last reviewed · How we verify
NCT06374563: ulcer
Tackling Pressure Ulcer Via Bee Venom Phonophoresis
NA trial testing group 1 received topical Bee venom gel in Bee Venom in 30 participants. Completed in 1 March 2024.
1 January 2024
Quick facts
| Lead sponsor | Badr University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 9 November 2022 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- group 1 received topical Bee venom gel
- Group 2: Phonophoresis of Bee Venom gel
Conditions studied
- Bee Venom — all drugs for Bee Venom →
- Pressure Ulcers — all drugs for Pressure Ulcers →
- Phonophoresis — all drugs for Phonophoresis →
Sponsor
Badr University
Who can join
Adults 40 to 60, any sex, with Bee Venom or Pressure Ulcers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to investigate the efficiency of topical Bee Venom gel versus phonophoresis of Bee Venom gel to accelerate healing of chronic pressure ulcer
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06374563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Badr University trials
Trials by the same sponsor.
- NCT07395895 — Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women · Phase 3 · not yet recruiting
- NCT07399743 — Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis · Phase 3 · not yet recruiting
- NCT07272967 — Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury · Phase 4 · not yet recruiting
- NCT07296146 — Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients. · Phase 3 · not yet recruiting
- NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06374563 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Badr University
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06374563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing